GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Median PS Value

QLIS (Qualis Innovations) Median PS Value : $0.00 (As of Dec. 11, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Qualis Innovations's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0. Qualis Innovations's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-12-11), Qualis Innovations's share price is $0.30019. Qualis Innovations's Median PS Value is $0.00. Therefore, Qualis Innovations's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Qualis Innovations's Median PS Value or its related term are showing as below:

QLIS's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.79
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Qualis Innovations Median PS Value Historical Data

The historical data trend for Qualis Innovations's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualis Innovations Median PS Value Chart

Qualis Innovations Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only - - - - -

Qualis Innovations Quarterly Data
Apr11 Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Qualis Innovations's Median PS Value

For the Medical Devices subindustry, Qualis Innovations's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qualis Innovations's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Qualis Innovations's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Qualis Innovations's Price-to-Median-PS-Value falls into.



Qualis Innovations Median PS Value Calculation

Qualis Innovations's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Qualis Innovations's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qualis Innovations  (OTCPK:QLIS) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Qualis Innovations's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.30019/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qualis Innovations Median PS Value Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualis Innovations Business Description

Traded in Other Exchanges
N/A
Address
6898 S. University Boulevard, Suite 100, Centennial, CO, USA, 80122
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality-agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751